Terlipressin Use and Respiratory Failure in Patients with Hepatorenal Syndrome Type 1 and Severe Acute-on-chronic Liver Failure

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2022 Aug 22

PMID 35995728

Authors

Florence Wong

Stephen Chris Pappas

K Rajender Reddy

Hugo Vargas

Michael P Curry

Arun Sanyal

Khurram Jamil

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute-on-chronic liver failure (ACLF).

Aim: To assess mortality and respiratory failure (RF) in patients with HRS1 and ACLF treated with terlipressin.

Methods: In the CONFIRM study, we randomised 299 patients with HRS1 2:1 to terlipressin or placebo, both with albumin. At enrolment, all patients were assessed for organ failure (OF) using a validated ACLF grading system. Post hoc analyses assessed the effects of terlipressin vs. placebo on the incidence of RF and 90-day mortality.

Results: The incidence of RF with terlipressin (n = 200) was 9.4% in patients with grades 1-2 ACLF, and 30% with grade 3 ACLF (p = 0.0002); no such difference was observed in placebo-treated patients (n = 99) (6.2% grades 1-2 vs. 0% grade 3 ACLF, p > 0.05). RF incidence between terlipressin and placebo in patients with grade 3 ACLF was significant (p = 0.01). Baseline predictors of RF with terlipressin were INR (p = 0.011), mean arterial pressure (p = 0.037), and SpO (p = 0.014). Prior albumin as a continuous variable was not a predictor of RF. 90-day survival between terlipressin and placebo arms was similar for grades 1-2 ACLF (55.5% and 56.6%, respectively), but lower for grade 3 ACLF (27.55% vs. 50.0%) (p = 0.122), mainly related to RF.

Conclusion: Terlipressin should be used with caution in patients with HRS1 and grade 3 ACLF. Patients with hypoxaemia are at increased risk of RF and mortality.

Citing Articles

Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis. Author's reply.

Nadim M, Forni L, Ostermann M Intensive Care Med. 2024; 51(1):215-216.

PMID: 39570402 DOI: 10.1007/s00134-024-07720-0.

Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis.

Wong F, Pappas S Intensive Care Med. 2024; 51(1):213-214.

PMID: 39441357 DOI: 10.1007/s00134-024-07681-4.

Comparative Mortality Rates of Vasoconstrictor Agents in the Management of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.

Olayinka O, Orelus J, Nisar M, Kotha R, Saad-Omer S, Singh S Cureus. 2024; 16(8):e67034.

PMID: 39286706 PMC: 11402629. DOI: 10.7759/cureus.67034.

Treatment of Hepatorenal Syndrome-Acute Kidney Injury: Advances Made but Challenges Remain.

Premkumar M, Reddy K Gastro Hep Adv. 2024; 2(4):547-548.

PMID: 39132035 PMC: 11308433. DOI: 10.1016/j.gastha.2023.02.005.

Terlipressin use in HRS-AKI and respiratory failure.

Arrestier R, Billiet P, Frapard T, Mekontso Dessap A Intensive Care Med. 2024; 50(10):1711-1712.

PMID: 39073583 DOI: 10.1007/s00134-024-07556-8.

References

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

Bajaj J, Moreau R, Kamath P, Vargas H, Arroyo V, Reddy K . Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology. 2018; 68(4):1621-1632. DOI: 10.1002/hep.30056. View

Casulleras M, Zhang I, Lopez-Vicario C, Claria J . Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells. 2020; 9(12). PMC: 7762372. DOI: 10.3390/cells9122632. View

Reiberger T . When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome?. Clin Gastroenterol Hepatol. 2018; 16(11):1710-1711. DOI: 10.1016/j.cgh.2018.04.020. View

Gines P, Sola E, Angeli P, Wong F, Nadim M, Kamath P . Hepatorenal syndrome. Nat Rev Dis Primers. 2018; 4(1):23. DOI: 10.1038/s41572-018-0022-7. View

Zaccherini G, Weiss E, Moreau R . Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep. 2020; 3(1):100176. PMC: 7652714. DOI: 10.1016/j.jhepr.2020.100176. View

Krag A, Bendtsen F, Mortensen C, Henriksen J, Moller S . Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol. 2010; 22(9):1085-92. DOI: 10.1097/MEG.0b013e32833a4822. View

Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B . A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008; 134(5):1360-8. PMC: 3730280. DOI: 10.1053/j.gastro.2008.02.014. View

Salerno F, Gerbes A, Gines P, Wong F, Arroyo V . Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56(9):1310-8. PMC: 1954971. DOI: 10.1136/gut.2006.107789. View

10.

Simonetto D, Gines P, Kamath P . Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020; 370:m2687. DOI: 10.1136/bmj.m2687. View

11.

Wong F, Pappas S, Curry M, Reddy K, Rubin R, Porayko M . Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021; 384(9):818-828. DOI: 10.1056/NEJMoa2008290. View

12.

Kalambokis G, Pappas K, Tsianos E . Differential effects of terlipressin on pulmonary and systemic hemodynamics in patients with cirrhosis and pulmonary hypertension: an echo study. Angiology. 2011; 63(3):199-205. DOI: 10.1177/0003319711411704. View

13.

Mahmud N, Sundaram V, Kaplan D, Taddei T, Goldberg D . Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. Hepatology. 2019; 72(1):230-239. PMC: 7195222. DOI: 10.1002/hep.31012. View

14.

Martin-Llahi M, Pepin M, Guevara M, Diaz F, Torre A, Monescillo A . Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9. DOI: 10.1053/j.gastro.2008.02.024. View

15.

Druml W . Systemic consequences of acute kidney injury. Curr Opin Crit Care. 2014; 20(6):613-9. DOI: 10.1097/MCC.0000000000000150. View

16.

Wong F, Pappas S, Reddy K, Vargas H, Curry M, Sanyal A . Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022; 56(8):1284-1293. PMC: 9804971. DOI: 10.1111/apt.17195. View

17.

Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J . A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2013; 41(1):3-11. PMC: 3918942. DOI: 10.1097/SHK.0000000000000052. View

18.

Boyer T, Sanyal A, Wong F, Frederick R, Lake J, OLeary J . Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016; 150(7):1579-1589.e2. DOI: 10.1053/j.gastro.2016.02.026. View

19.

Israelsen M, Dahl E, Madsen B, Wiese S, Bendtsen F, Moller S . Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. Am J Physiol Gastrointest Liver Physiol. 2019; 318(2):G313-G321. DOI: 10.1152/ajpgi.00328.2019. View

20.

Claria J, Stauber R, Coenraad M, Moreau R, Jalan R, Pavesi M . Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016; 64(4):1249-64. DOI: 10.1002/hep.28740. View